VANDA PHARMACEUTICALS INC. Payments to Acquire Intangible Assets
VANDA PHARMACEUTICALS INC. (VNDA) reported Payments to Acquire Intangible Assets of $10.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireIntangibleAssets · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. payments to acquire intangible assets for the quarter ending 2026-06-30 was $0.00.
- VANDA PHARMACEUTICALS INC. payments to acquire intangible assets for the quarter ending 2026-03-31 was $10.00M.
- VANDA PHARMACEUTICALS INC. payments to acquire intangible assets for the quarter ending 2025-06-30 was $0.00.
- VANDA PHARMACEUTICALS INC. payments to acquire intangible assets for the quarter ending 2025-03-31 was $0.00.
- VANDA PHARMACEUTICALS INC. payments to acquire intangible assets for fiscal 2020 was $0.00.
- VANDA PHARMACEUTICALS INC. payments to acquire intangible assets for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- VANDA PHARMACEUTICALS INC. payments to acquire intangible assets for fiscal 2018 was $25.00M.
- VANDA PHARMACEUTICALS INC. payments to acquire intangible assets for fiscal 2017 was $0.00.
| Period end | Payments to Acquire Intangible Assets 1 month | Payments to Acquire Intangible Assets 3 month | Payments to Acquire Intangible Assets 6 month | Payments to Acquire Intangible Assets 9 month | Payments to Acquire Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.00M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $10.00M 10-Q · filed 2026-05-07 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | ||||
| 2020-12-31 | $0.00 10-K · filed 2021-02-11 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | $0.00 10-K · filed 2021-02-11 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-01 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | $25.00M 10-K · filed 2021-02-11 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $25.00M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $25.00M 10-Q · filed 2019-08-01 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-26 | $0.00 10-K · filed 2020-02-26 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-02 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-19 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | $0.00 derived: sum of 3 quarters · filed 2017-02-17 | $8.00M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $0.00 derived: sum of 2 quarters · filed 2015-11-04 | $8.00M 10-Q · filed 2015-11-04 | ||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $8.00M 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | $8.00M 10-Q · filed 2015-05-07 | ||||
| 2013-07-31 | $3.00M 10-Q · filed 2015-05-07 | ||||
| 2012-06-30 | $12.00M 10-Q · filed 2012-08-03 | ||||
| 2009-12-31 | $12.00M 10-K · filed 2012-03-09 | ||||
| 2009-05-31 | $12.00M 10-Q · filed 2013-07-31 | ||||
| 2006-12-31 | $1.00M 10-Q · filed 2015-05-07 | ||||
| 2004-02-28 | $500.00K 10-Q · filed 2015-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |